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Abstract Severe loss of body height is often a conse-
quence of osteoporotic vertebral fractures. Osteoprotegerin
(OPG) and receptor activator of nuclear factor-kB ligand
(RANKL) are cytokines essential for the regulation of bone
resorption. The aim of this study was to assess the rela-
tionship between the OPG/RANKL system and height loss.
A total of 4,435 inhabitants from the municipality of
Tromsø, Norway (2,169 men and 2,266 women) were
followed for 6 years. Baseline measurements included
height, weight, bone mineral density, OPG, RANKL,
serum parathyroid hormone and information about life-
style, prevalent diseases and use of medication. Height was
measured again at follow-up, and the loss of height was
categorized into 4 groups: B1, 1.1–2, 2.1–3, [3 cm. We
found increasing height loss with increasing baseline OPG
levels in both men and women (P trend = 0.02 and 0.001,
respectively), after adjustments for age and other con-
founders. However, when the women were stratiﬁed
according to menopausal status and use of hormone
replacement therapy (HRT), a signiﬁcant relationship was
present only among postmenopausal women not using
HRT (P trend = 0.02). No relations between OPG and
height loss were found in post-menopausal HRT-users and
premenopausal women (P trend C0.39). We conclude that
height loss is positively associated with OPG in men and in
postmenopausal women not using HRT. No relationship
was found between RANKL and height loss.
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Introduction
Height loss increases with age and is related to aging
chances in joints, muscles and bone. While a minor degree
of height loss is common and probably not associated with
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3–7 years) is often a consequence of osteoporotic vertebral
fractures [1–7].
Osteoprotegerin (OPG) and receptor activator of nuclear
factor-kB ligand (RANKL) are cytokines essential for the
regulation of bone resorption [8, 9]. Osteoclastogenesis and
bone resorption is induced when RANKL binds to its
receptor RANK on osteoclast precursors promoting osteo-
clast maturation and activation. This binding may, however,
be prevented by OPG, which competitively binds RANKL,
whereby osteoclast differentiation, activation and survival
are inhibited [10]. The OPG/RANKL system is a key regu-
lator of osteoclastogenesis, but also an important link
between a number of cytokines and hormones including sex
steroids, the immune system (TNF-alpha, interleukins, glu-
cocorticoids), parathyroid hormone and bone turnover [11].
Previous studies have shown that women tend to loose
more height than men after the age of 50 [12, 13], that
height loss is positively related to bone loss of the forearm
and lumbar spine in women [14, 15] and that bone loss
increases with increasing OPG levels in postmenopausal
women not using HRT [16]. Only few studies have
examined the effect of OPG or RANKL on fracture risk in
humans. The cross-sectional studies have found either
decreased [17] or increased [18] OPG levels in postmen-
opausal women with prevalent fractures. In studies of
persons followed longitudinally, one study found no asso-
ciation between OPG and all types of self-reported frac-
tures in postmenopausal women [19], another study found
that low RANKL levels were associated with an increased
risk of non-traumatic fracture in both men and women [20].
No longitudinal studies have been performed with regard to
vertebral fractures speciﬁcally.
Because severe height loss may serve as a proxy for
vertebral fractures, we assessed the relationship between
the OPG/RANKL system and the loss of height in
participants of a large population-based prospective study.
Materials and methods
Study population
The Tromsø Study is a population-based, longitudinal
study with repeated health surveys of inhabitants in the
municipality of Tromsø, Norway. It focuses on chronic and
lifestyle related conditions such as atherosclerosis and
osteoporosis. The regional ethical committee approved the
survey, and the participants gave written informed consent.
The subjects included in our analyses constitute a group
of men and women who were subject to ultrasonography of
the carotid artery twice, in the 4th and 5th surveys of
Tromsø Study in 1994 and 2001, respectively. At the fourth
survey in 1994–1995, all inhabitants aged 55–74 years, and
5–10% random samples of the other 5-year birth cohorts
older than 24 years of age were invited to participate in a
two-part survey. The ﬁrst part included standardized
measurements of height, body weight, blood pressure and
non-fasting serum lipids; the second part (4–12 weeks
later) included measurements of bone mineral density and
carotid ultrasonography. A total of 6,727 subjects (74% of
the eligible population) completed the examination.
Seven years later, in 2001, allof these 6,727 subjectswho
were still living in the municipality (had not died or moved
out of Tromsø) were invited to a repeated examination. This
was conducted in 4,858 subjects (82% of the eligible and
72% of the original baseline cohort). However, information
about OPG, RANKL, bone mineral density or height (in
1994 or 2001) was missing in 372 subjects. The available
information concerning menstruation [16] was missing or
inconsistent in 51 women, and these women were excluded.
Thus, 2,169 men and 2,266 women were included in the
present analyses. The persons with follow-up measurements
were younger than those we did not follow. Moreover, the
prevalenceofsmokinginthe former group was lower,fewer
were teetotallers, and they were more physically active and
had a lower prevalence of cardiovascular diseases.
Among the 2,266 women included in the study, 248
were classiﬁed as premenopausal and 2,018 were classiﬁed
as postmenopausal. In the latter group, 422 used HRT and
1,596 did not.
Measurements
In 1994–1995, information about smoking and alcohol
habits, physical activity, prevalent cardiovascular diseases
and (for women) use of HRT and menopausal status was
collected from self-administered questionnaires [21].
Height was measured to the nearest centimeter with a wall-
mounted ruler, a method that is as precise as a stadiometer
[22], and weight was measured to the nearest half-kilo-
gram. For both measurements the subjects were wearing
light clothing and no shoes. Body mass index was calcu-
lated as weight in kilograms divided by the square of height
in meters (kg/m
2). Anthropometric measurements were
performed in the same way in the ﬁfth survey in
2001–2002.
The concentrations of total OPG and RANKL were ana-
lyzed in frozen serum aliquots stored at -70C. OPG was
analyzedbyanELISAassay(R&DSystems,Abingdon,UK)
with mouse anti-human OPG as capture antibody. Biotin-
ylated goat anti-human OPG and streptavidin horseradish
peroxydase were used for detection. The OPG assay was
performedaccordingtotheinstructionsbythemanufacturer.
Thedetectionlimitwas62.5 pg/ml.Theintra-andinterassay
coefﬁcientsofvariationinourlaboratorywere3.2and6.8%,
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123respectively. Between-assay variation in OPG was adjusted
for by use of an internal standard.
The concentration of RANKL was measured by a new,
highly sensitive ELISA assay for free (soluble) RANKL
with a detection limit of 0.02 pmol/l (ampli sRANKL
human, Biomedica, Vienna, Austria). The analysis was
performed according to the manufacturer’s instruction. The
intra- and inter-assay coefﬁcients of variation for the
RANKL assay were 9.3 and 15.0%, respectively.
Intact serum parathyroid hormone was analysed by
sandwich test principle with monoclonal antibodies reac-
tive to epitopes in the amino acids regions 26–32 and
37–42 (reagents from Roche Diagnostics GmbH, Mann-
heim, Germany), in a Modular E Autoanalyzer (Roche
Diagnostics). The analytical coefﬁcient of variation was
\3%.
All analyses were performed on coded samples without
knowledge of status regarding changes in body height by
the person performing the assays. All samples were ana-
lyzed in duplicate and the mean value is used in this report.
BMD of the distal and ultradistal forearm was assessed
as previously described with single X-ray absorptiometry
(DTX-100, Osteometer MediTech, Inc., Hawthorne, CA,
USA), and all scans were reviewed in order to detect and
correct possible artifacts before analysis [23]. A total of
111 subjects had repeated measurements. The median
coefﬁcients of variations for two scans performed 1 week
apart by two different operators were 0.79 and 0.98% at the
distal and ultradistal sites, respectively [24]. BMD was
measured in a similar way at follow up in 2001–2002 in
4,116 of the persons who were included at baseline.
Statistical analysis
Characteristics of the study population are presented as
means (SD) for continuous variables or percentages for
dichotomous variables. RANKL levels below 0.02 pmol/l
(the limit of detection) were set to 0.01 pmol/l, and because
the RANKL levels were not normally distributed they are
presented as median as well.
The baseline characteristics of the participants (men,
and women stratiﬁed with respect to postmenopausal status
and HRT-use) were compared by use of ANCOVA with
adjustments for age.
The participants were divided into 4 groups with respect
to loss of body height during follow-up: B1, 1.1–2, 2.1–3,
[3 cm, and baseline OPG levels for these different groups
were assessed by use of ANCOVA with adjustments for
potential confounders. Trends over the groups were tested
using multiple regression analyses.
Multiple regression analyses were also used when height
loss as a continuous variable was used rather than height
loss groups. Possible differences in the associations
between OPG and height loss in the different groups of
women were tested by including interaction terms in the
model.
Similar analyses were performed for RANKL. The
RANKL values were also compared after they had been
logarithmically transformed.
A two-sided P value\0.05 was considered statistically
signiﬁcant.
The data were analyzed using the Windows 15.0 version
of SPSS.
Results
The baseline characteristics of the study groups are pre-
sented in Table 1.
Age-adjusted comparisons between the groups showed
that they differed signiﬁcantly with respect to all variables
presented in the table, except for serum parathyroid hor-
mone levels and RANKL (log transformed). Moreover, the
age at menopause did not differ between the postmeno-
pausal women who were users and non-users of HRT.
Table 2 shows that the age adjusted OPG levels
increased with increasing height loss in both women and
men (P trend B0.001 and 0.007, respectively). The rela-
tionships were very similar after adjustments for body mass
index, smoking habits, physical inactivity, prevalent car-
diovascular disease, serum parathyroid hormone and BMD
of the distal forearm (Table 2). In the subgroup of 4,116
persons (2,124 women and 1,992 men) with measurements
of BMD at follow-up, the results were almost the same
after adjustments for change in BMD instead of BMD
baseline measurements (results not shown).
When the women were stratiﬁed according to meno-
pausal status and use of HRT, a signiﬁcant relationship was
present only among postmenopausal women not using
HRT (P trend = 0.02, after multiple adjustments). No
relations between OPG and height loss were found in post-
menopausal HRT-users or in premenopausal women
(P trend C0.39). The adjusted association between OPG
level and height loss in postmenopausal women not using
HRT was statistically signiﬁcantly different from that in
premenopausal women (P = 0.001), but not statistically
signiﬁcantly different from that in postmenopausal women
using HRT (P = 0.7).
With height loss as a continuous variable (instead of
height loss groups) OPG increased by 0.05 ng (P = 0.002)
and 0.02 ng (P = 0.6) per cm height loss in postmeno-
pausal women not using and using HRT, respectively, and
decreased by 0.05 ng per cm height loss (P = 0.6) in
premenopausal women.
RANKL levels were not related to height loss in men or
in any of the groups of women (P trend C0.24) (Table 2).
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ted to height loss (P trend C0.24), (results not shown in the
table).
BMD of the distal and ultradistal forearm correlated sig-
niﬁcantly with each other (r = 0.9, P\0.001) and adjust-
ments for BMD of the ultradistal site gave similar results as
those reported for the distal forearm (results not shown).
Discussion
In this population-based study, increasing serum OPG
levels were associated with height loss in men and in
postmenopausal women not using HRT, whereas no rela-
tionship was found in premenopausal women or postmen-
opausal women taking HRT. RANKL was not related to
height loss in any of the groups.
Height loss is associated with age related changes of the
posture, decreasing height of the intervertebral discs and
lower muscle strength. However, height loss is also
strongly related to the development of osteoporosis, and in
longitudinal studies of elderly women with repeated mea-
surements of height, a loss of C2 centimetres during
3–7 years indicate vertebral fracture [4, 7]. In older
women, height loss is also associated with excess BMD
decline and an increased risk of all fracture types [25].
The present study is the ﬁrst to examine the relationship
between the OPG/RANKL system and height loss. No
longitudinal studies have been performed with regard to
vertebral fractures speciﬁcally, but in a prospective study
of 490 postmenopausal women, no association was found
between OPG and all types of self reported fractures [19].
However, in a post-hoc analysis, the women who sustained
a hip fracture had higher OPG levels. In another study
Schett et al. [20] found that low RANKL levels were
associated with an increased risk of non-traumatic fracture
in both men and women.
Several cross-sectional studies have examined the rela-
tionship between BMD and OPG, ﬁnding no association
[19, 26–36], a positive [37] and an inverse relationship
between the two [18, 38–40]. Only few longitudinal studies
are available, and whereas we found that high OPG levels
were associated with bone loss in postmenopausal women
not using HRT [16], two other (but much smaller) studies
found no relationship [34, 41]. RANKL was not related to
bone loss in any of these studies.
In the present study we show that the relationship
between height loss and OPG was not explained by BMD.
One may speculate that although OPG seems to be a
marker of BMD loss, it may also be a marker of other
structural changes of the vertebrae, such as changes in the
micro-architecture of the bone, which we did not measure.
Although we cannot exclude that OPG is related to other
factors that inﬂuences changes in posture (e.g., muscle
strength and intervertebral disc height), we believe that this
is unlikely.
Table 1 Characteristics of the study population
Men Women
Premenopausal
non-users of HRT
Postmenopausal
users of HRT
Postmenopausal
non-users of HRT
Characteristics (n = 2,169) (n = 248) (n = 422) (n = 1,596)
Age, years
a 59.0 (9.2) 38.7 (6.9) 60.9 (6.1) 63.4 (5.9)
Height, (cm)
a 175.5 (6.7) 165.0 (6.5) 161.6 (5.7) 161.2 (6.1)
Body mass index, (kg/m
2)
a 26.1 (3.2) 24.0 (3.7) 25.8 (3.8) 26.3 (4.3)
Smoker, (%) 31 44 21 29
Physically inactive, (%) 33 40 38 47
Self-reported cardiovascular diseases, (%) 15 0.4 7 11
Age at menopause, (years)
a – – 48.7 (5.0) 48.4 (4.8)
Bone mineral density, distal forearm, (mg/cm
2)
a 544.1 (62.9) 467.8 (44.8) 406.4 (66.0) 387.2 (65.2)
Bone mineral density, ultradistal forearm, (mg/cm
2)
a 445.3 (67.3) 369.8 (49.5) 307.3 (62.7) 289.1 (60.0)
Serum parathyroid hormone, (pmol/l)
a 4.1 (1.7) 3.7 (1.3) 4.2 (1.6) 4.3 (1.8)
OPG (ng/ml)
a 3.07 (0.86) 2.55 (0.78) 3.07 (0.83) 3.53 (0.89)
RANKL (pmol/l)
a 0.10 (0.15) 0.12 (0.19) 0.11 (0.19) 0.10 (0.17)
RANKL (pmol/l), median 0.053 0.057 0.050 0.043
Six years height loss, (cm)
a 0.9 (1.1) 0.4 (0.5) 0.8 (0.9) 1.1 (1.2)
HRT hormone replacement therapy, OPG osteoprotegerin, RANKL soluble nuclear factor-kB ligand
a Values are means (SD)
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123Experimental data from animals have shown that the
deletion of the OPG gene promoted severe osteoporosis in
mice, and that in transgenic mice overexpression of OPG
from midgestation completely prevented the lesions [42].
Moreover, mice with targeted deletion of the RANKL gene
developed osteopetrosis [43] whereas parenteral adminis-
tration of RANKL led to massive osteoporosis [44].
Modulation of the OPG-RANKL system has a signiﬁcant
impact on BMD and fracture risk also in humans. Deno-
sumab is a fully human monoclonal antibody to RANKL
that blocks its binding to RANK, and it was recently shown
that treatment with Denosumab reduced bone resorption
and increased BMD, but most importantly reduced the risk
of vertebral, non-vertebral, and hip fractures in postmen-
opausal women with osteoporoses [45]. It has therefore
been speculated that the high OPG levels found in some
studies of humans with low bone mass may reﬂect an
attempt to counter balance the development of
osteoporosis.
The development of osteoporosis is clearly related to
estrogen deﬁcit in women, but recent studies have shown
that estradiol also seems to play an important role regard-
ing the risk of vertebral and non-vertebral fracture in
elderly men [46–48]. In the present study high OPG levels
Table 2 OPG and RANKL levels in relation to height loss
Height loss
B1 cm 1.1–2 cm 2.1–3 cm [3c m P trend P trend
a
Men, all
n 1,455 491 142 81
OPG (ng/ml)
b 3.05 (3.01–3.08) 3.06 (3.00–3.13) 3.28 (3.15–3.40) 3.14 (2.98–3.30) 0.007
OPG (ng/ml)
c 3.05 (3.01–3.09) 3.07 (3.00–3.13) 3.26 (3.13–3.38) 3.12 (2.96–3.28) 0.02
RANKL (pmol/l)
b 0.10 (0.09–0.11) 0.10 (0.09–0.12) 0.09 (0.06–0.11) 0.08 (0.05–0.11) 0.17 0.30
RANKL (pmol/l)
c 0.10 (0.09–0.11) 0.10 (0.09–0.12) 0.09 (0.06–0.11) 0.08 (0.05–0.11) 0.24 0.42
Women, all
n 1,447 530 188 101
OPG (ng/ml)
b 3.30 (3.26–3.35) 3.33 (3.26–3.40) 3.46 (3.35–3.58) 3.61 (3.45–3.77) \0.001
OPG (ng/ml)
c 3.31 (3.27–3.35) 3.33 (3.26–3.40) 3.43 (3.31–3.55) 3.59 (3.43–3.75) 0.001
RANKL (pmol/l)
b 0.11 (0.10–0.12) 0.10 (0.09–0.12) 0.10 (0.08–0.13) 0.11 (0.07–0.14) 0.80 0.80
RANKL (pmol/l)
c 0.11 (0.10–0.12) 0.10 (0.09–0.12) 0.10 (0.08–0.13) 0.11 (0.08–0.15) 0.89 0.64
Postmenopausal non-users of HRT
n 952 399 154 91
OPG (ng/ml)
b 3.50 (3.45–3.55) 3.53 (3.46–3.61) 3.59 (3.46–3.72) 3.74 (3.57–3.90) 0.008
OPG (ng/ml)
c 3.51 (3.46–3.56) 3.53 (3.45–3.61) 3.57 (3.44–3.70) 3.73 (3.57–3.90) 0.02
RANKL (pmol/l)
b 0.10 (0.09–0.12) 0.10 (0.08–0.11) 0.10 (0.07–0.13) 0.11 (0.07–0.14) 0.74 0.95
RANKL (pmol/l)
c 0.11 (0.09–0.12) 0.10 (0.08–0.12) 0.10 (0.07–0.13) 0.11 (0.07–0.14) 0.86 0.83
Postmenopausal users of HRT
n 282 99 31 10
OPG (ng/ml)
b 3.06 (2.98–3.15) 3.03 (2.89–3.17) 3.21 (2.95–3.47) 3.01 (2.57–3.46) 0.74
OPG (ng/ml)
c 3.05 (2.97–3.14) 3.01 (2.87–3.16) 3.18 (2.92–3.45) 3.01 (2.56–3.46) 0.83
RANKL (pmol/l)
b 0.11 (0.09–0.14) 0.12 (0.08–0.16) 0.12 (0.05–0.19) 0.08 (-0.04–0.21) 0.88 0.80
RANKL (pmol/l)
c 0.11 (0.09–0.14) 0.12 (0.08–0.16) 0.12 (0.04–0.19) 0.09 (-0.04–0.21) 0.96 0.55
Premenopausal non-users of HRT
n 213 32 3 0
OPG (ng/ml)
b 2.57 (2.46–2.67) 2.45 (2.17–2.72) 2.32 (1.42–3.21) – 0.35
OPG (ng/ml)
c 2.57 (2.46–2.67) 2.46 (2.18–2.75) 2.28 (1.37–3.19) – 0.39
RANKL (pmol/l)
b 0.12 (0.09–0.14) 0.13 (0.06–0.19) 0.09 (-0.12–0.31) – 0.92 0.65
RANKL (pmol/l)
c 0.12 (0.09–0.14) 0.13 (0.06–0.20) 0.11 (-0.11–0.33) – 0.80 0.67
OPG osteoprotegerin; mean (95% CI), RANKL, soluble nuclear factor-kB ligand; mean (95% CI), HRT hormone replacement therapy
a P trend for log transformed values
b Adjusted for age
c Adjusted for age, body mass index, smoking, physical inactivity, cardiovascular diseases (previous myocardial infarction or angina pectoris or
stroke); bone mineral density distal forearm, and serum parathyroid hormone
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postmenopausal women not using HRT.
The present study has some limitations. We suspect that
vertebral fractures were common in the groups with the
highest height loss, as previous studies have found that a
height loss of C2 cm, calculated from actual measure-
ments, indicate fracture [4, 7]. However, the study would
clearly have been strengthened if we had been able to
assess the incidence of vertebral fractures during follow-up
and assess whether these fractures were due to osteoporosis
[49].
Another limitation is related to the fact that serum
concentrations of OPG and RANKL are produced by many
tissues and do not fully reﬂect the local milieu within the
bone microenvironment. In addition, most RANKL is cell-
bound and not detected in the circulation. Furthermore,
37% of our population has serum RANKL levels below the
limit of detection. This percentage is lower than in most
previous studies, but the interpretation of the relationship
between height loss and RANKL (as well as the OPG/
RANKL ratio) is limited due to the relatively high per-
centage of participants with undetectable RANKL.
There were 248 premenopausal women and 422 post-
menopausal women who used HRT included in the anal-
yses, and these low numbers may imply power limitations.
For the premenopausal women there was an inverse rela-
tionship (decreasing OPG levels with increasing height
loss) contrary to what we found for postmenopausal
women who did not use HRT, and the association in the
two groups of women was statistically signiﬁcantly dif-
ferent. This signiﬁcant interaction seems to support the
hypothesis that the relationship is inﬂuenced by estrogen
levels. The relationship in the postmenopausal women who
did or did not use HRT was not signiﬁcantly different,
however, and we can not exclude that if the number of
postmenopausal women using HRT had been higher, a
positive relationship between height loss and OPG would
have been found also in this group of women.
A concern is also related to the possibility of bias.
Although our study group was large and had a high
attendance rate, severely ill or disabled individuals were
underrepresented. Moreover, the persons with follow-up
measurements were younger and healthier than those we
did not follow. However, if such bias should contribute to
the ﬁndings of a relationship between OPG and height loss
in men and postmenopausal women not using HRT, the
loss of height would have to be very strongly associated
with lower OPG levels among the non-participants in these
groups. We believe that this is unlikely and that it is more
plausible that non-participation may have weakened the
actual relationship.
We conclude that height loss is positively associated
with OPG in men and in postmenopausal women not using
HRT. No relationship is found in premenopausal women or
postmenopausal women taking HRT. We call for longitu-
dinal studies on the relationship between the OPG/RANKL
system and incident vertebral fracture.
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